Bayer had a net loss of approximately 10.5 billion euros last year, and the top sales of rivaroxaban faced a patent cliff

On the 25th local time, Bayer announced its 2020 fiscal year, with total annual revenue of 41.

Among its four main businesses, Bayer's pharmaceutical business achieved revenue of 17.

In 2020, Bayer’s best-selling drug is the anticoagulant Xarelto (rivaroxaban).

Xarelto is the most widely used non-vitamin K antagonist oral anticoagulant (NOAC) in the world, developed by Bayer and Johnson & Johnson.

However, the top-selling rivaroxaban patent has expired in China in 2020, and it will also expire in EU countries in 2023, the United States in 2024, and Japan in 2025.

Also facing the patent cliff is not only the top spot, but also the second-ranked ophthalmic drug Eylea (Aflibercept), which was jointly developed by Bayer and Regeneron.

To this end, Bayer also announced in September last year that it will accelerate the pace of transformation.

From a strategic perspective, Bayer focuses on specific areas of cell and gene therapy, including stem cell therapy for different indications (focusing on induced pluripotent stem cells or iPSCs), gene enhancement, gene editing, and allogeneic cells therapy.